Current Report Filing (8-k)
August 09 2019 - 4:31PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
August 9, 2019
Mustang Bio, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
|
|
001-38191
|
|
47-3828760
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
2 Gansevoort
Street, 9th Floor
New York, New York 10014
(Address of Principal Executive Offices)
(781) 652-4500
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act.
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act.
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange Act.
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share
|
MBIO
|
NASDAQ Global Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
|
Item
2.02
|
Results
of Operations and Financial Condition.
|
On
August 9, 2019, Mustang Bio, Inc. issued a press release to provide a corporate update and to announce its financial results for
the second quarter ended June 30, 2019. A copy of such press release is being furnished as Exhibit 99.1 to this report.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
The following exhibit is furnished herewith:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Mustang Bio, Inc.
|
|
|
(Registrant)
|
|
Date: August 9, 2019
|
|
|
By:
|
/s/ Manuel Litchman, M.D.
|
|
|
|
Manuel Litchman, M.D.
|
|
|
President and Chief Executive Officer
|
Mustang Bio (NASDAQ:MBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mustang Bio (NASDAQ:MBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024